Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

Claire Roddie,Juliana Dias,Maeve A. OReilly,Mahnaz Abbasian,Amaia Cadinanos Garai,Ketki Vispute,Leticia Bosshard-Carter,Marina Mitsikakou,Vedika Mehra,Harriet Roddy,John A. Hartley,Victoria J. Spanswick,Helen Lowe,Bilyana Popova,Laura Clifton-Hadley,Graham Wheeler,Joanna Olejnik,Adrian Bloor,David Irvine,Leigh Wood,Maria A. V. Marzolini,Sabine Domning,Farzin Farzaneh,Mark W. Lowdell,David C. Linch,Martin Pule,Karl S. Peggs

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

2021

PURPOSEPrognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. We developed a novel second-ge...

Keywords:

low toxicity
Refractory
CD19
B-cell acute lymphoblastic leukemia
Chimeric antigen receptor
Cancer research
off rate
Lymphoblastic Leukemia
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations